Speech-Language Pathologists in Gaylord, MI Accepting Medicare

6 Speech-Language Pathologists found. Showing 1 - 6

Faith Brinkman, M.A., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5045 Manuka Trl, Gaylord, MI 49735 Phone: 989-732-7617    Fax: 989-731-7787

Breeanne Eckstein, MA CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1788 Snow Owl Ct, Gaylord, MI 49735 Phone: 989-350-8014

Shannon Mellema Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 825 N Center Ave, Gaylord, MI 49735 Phone: 989-731-3894    Fax: 989-731-7787

Alexis Ann Anderson Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 508 Random Ln, Gaylord, MI 49735 Phone: 517-937-1420

Michelle Reidt, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 825 N Center Ave, Gaylord, MI 49735 Phone: 989-731-2341

Samantha Paige Conklin, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 508 Random Ln, Gaylord, MI 49735 Phone: 989-732-3508

News Archive

International researchers discover 44 novel gene sites linked to hypertension

In papers receiving advance online publication in Nature Genetics, two international multi-institutional research teams describe identifying a total of 44 novel gene sites associated with hypertension or high blood pressure.

E. coli asparaginase linked to relapses in ALL patients with special form of ATF5 gene

One of the causes of resistance to cancer treatment in children is now beginning to be elucidated. Acute lymphoblastic leukemia patients with a particular form of the ATF5 gene are at higher risk of having a relapse when treated with E. coli asparaginase, a key chemotherapy drug for this type of leukemia.

Patients with leukemia or lymphoma who undergo hematopoietic-cell transplantation and survive can expect full recovery to take 3-5 years

Patients with leukemia or lymphoma who undergo hematopoietic-cell transplantation (HCT) and survive can expect full recovery to take 3-5 years, according to a study published in the May 19 issue of The Journal of the American Medical Association (JAMA).

Combination therapy improves survival rates in patients with advanced non-small cell lung cancer

A combination therapy for treating cancer discovered at the University of Colorado Cancer Center showed improved survival rates in patients with advanced non-small cell lung cancer (NSCLC), according to results from a double-blind, placebo-controlled phase 2 trial run by Syndax Pharmaceuticals.

Read more Medical News

› Verified 4 days ago